AT505574B1 - Mimotope zur behandlung von atherosklerose - Google Patents

Mimotope zur behandlung von atherosklerose Download PDF

Info

Publication number
AT505574B1
AT505574B1 AT0125807A AT12582007A AT505574B1 AT 505574 B1 AT505574 B1 AT 505574B1 AT 0125807 A AT0125807 A AT 0125807A AT 12582007 A AT12582007 A AT 12582007A AT 505574 B1 AT505574 B1 AT 505574B1
Authority
AT
Austria
Prior art keywords
leu
cetp
ser
prt
artificial sequence
Prior art date
Application number
AT0125807A
Other languages
German (de)
English (en)
Other versions
AT505574A1 (de
Original Assignee
Affiris Forschungs & Entwicklungs Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AT0125807A priority Critical patent/AT505574B1/de
Application filed by Affiris Forschungs & Entwicklungs Gmbh filed Critical Affiris Forschungs & Entwicklungs Gmbh
Priority to TW097130215A priority patent/TWI442933B/zh
Priority to AU2008286667A priority patent/AU2008286667B2/en
Priority to HRP20131229AT priority patent/HRP20131229T1/hr
Priority to JP2010520379A priority patent/JP2010535818A/ja
Priority to PT87828091T priority patent/PT2190451E/pt
Priority to KR1020107005287A priority patent/KR20100080507A/ko
Priority to ES08782809.1T priority patent/ES2439703T3/es
Priority to CN2008801113067A priority patent/CN101835483B/zh
Priority to SI200831094T priority patent/SI2190451T1/sl
Priority to PL08782809T priority patent/PL2190451T3/pl
Priority to US12/673,081 priority patent/US8618046B2/en
Priority to EP08782809.1A priority patent/EP2190451B1/en
Priority to PCT/AT2008/000281 priority patent/WO2009021254A1/en
Priority to DK08782809.1T priority patent/DK2190451T3/da
Priority to CA2695988A priority patent/CA2695988A1/en
Priority to HK10112056.4A priority patent/HK1145634B/xx
Publication of AT505574A1 publication Critical patent/AT505574A1/de
Application granted granted Critical
Publication of AT505574B1 publication Critical patent/AT505574B1/de
Priority to JP2013198877A priority patent/JP2014040438A/ja
Priority to US14/086,159 priority patent/US20140179900A1/en
Priority to CY20141100039T priority patent/CY1114760T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0012—Lipids; Lipoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT0125807A 2007-08-10 2007-08-10 Mimotope zur behandlung von atherosklerose AT505574B1 (de)

Priority Applications (20)

Application Number Priority Date Filing Date Title
AT0125807A AT505574B1 (de) 2007-08-10 2007-08-10 Mimotope zur behandlung von atherosklerose
US12/673,081 US8618046B2 (en) 2007-08-10 2008-08-08 Treatment of atherosclerosis with cholesterol ester transport protein mimotopes
HRP20131229AT HRP20131229T1 (hr) 2007-08-10 2008-08-08 Lijeäśenje ateroskleroze
JP2010520379A JP2010535818A (ja) 2007-08-10 2008-08-08 アテローム性動脈硬化の治療
PT87828091T PT2190451E (pt) 2007-08-10 2008-08-08 Tratamento da aterosclerose
KR1020107005287A KR20100080507A (ko) 2007-08-10 2008-08-08 죽상경화증의 치료
ES08782809.1T ES2439703T3 (es) 2007-08-10 2008-08-08 Tratamiento de la aterosclerosis
CN2008801113067A CN101835483B (zh) 2007-08-10 2008-08-08 动脉粥样硬化的治疗
SI200831094T SI2190451T1 (sl) 2007-08-10 2008-08-08 Zdravljenje ateroskleroze
PCT/AT2008/000281 WO2009021254A1 (en) 2007-08-10 2008-08-08 Treatment of atherosclerosis
TW097130215A TWI442933B (zh) 2007-08-10 2008-08-08 胜肽、醫藥化合物及該醫藥化合物之使用
AU2008286667A AU2008286667B2 (en) 2007-08-10 2008-08-08 Treatment of atherosclerosis
PL08782809T PL2190451T3 (pl) 2007-08-10 2008-08-08 Leczenie miażdżycy
DK08782809.1T DK2190451T3 (da) 2007-08-10 2008-08-08 Behandling af atherosklerose
CA2695988A CA2695988A1 (en) 2007-08-10 2008-08-08 Treatment and/or prevention of atherosclerosis peripheral arterial occlusive disease, coronary heart disease or apoplectic cerebral insultus
HK10112056.4A HK1145634B (en) 2007-08-10 2008-08-08 Treatment of atherosclerosis
EP08782809.1A EP2190451B1 (en) 2007-08-10 2008-08-08 Treatment of atherosclerosis
JP2013198877A JP2014040438A (ja) 2007-08-10 2013-09-25 アテローム性動脈硬化の治療
US14/086,159 US20140179900A1 (en) 2007-08-10 2013-11-21 Treatment of atherosclerosis with cholesterol ester transport protein mimotopes
CY20141100039T CY1114760T1 (el) 2007-08-10 2014-01-16 Θεραπευτικη αγωγη αθηροσκληρωσης

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0125807A AT505574B1 (de) 2007-08-10 2007-08-10 Mimotope zur behandlung von atherosklerose

Publications (2)

Publication Number Publication Date
AT505574A1 AT505574A1 (de) 2009-02-15
AT505574B1 true AT505574B1 (de) 2009-09-15

Family

ID=39865273

Family Applications (1)

Application Number Title Priority Date Filing Date
AT0125807A AT505574B1 (de) 2007-08-10 2007-08-10 Mimotope zur behandlung von atherosklerose

Country Status (17)

Country Link
US (2) US8618046B2 (enExample)
EP (1) EP2190451B1 (enExample)
JP (2) JP2010535818A (enExample)
KR (1) KR20100080507A (enExample)
CN (1) CN101835483B (enExample)
AT (1) AT505574B1 (enExample)
AU (1) AU2008286667B2 (enExample)
CA (1) CA2695988A1 (enExample)
CY (1) CY1114760T1 (enExample)
DK (1) DK2190451T3 (enExample)
ES (1) ES2439703T3 (enExample)
HR (1) HRP20131229T1 (enExample)
PL (1) PL2190451T3 (enExample)
PT (1) PT2190451E (enExample)
SI (1) SI2190451T1 (enExample)
TW (1) TWI442933B (enExample)
WO (1) WO2009021254A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT506535B1 (de) * 2008-02-22 2010-04-15 Affiris Forschungs & Entwicklungs Gmbh Vaccine enthaltend alpha-synuclein-mimotope auf basis von peptiden
EP2532359A1 (en) 2011-06-10 2012-12-12 Affiris AG CETP fragments
EP3733868A3 (en) 2013-10-28 2021-01-13 DOTS Technology Corp. Allergen detection
CN105596811A (zh) * 2015-11-10 2016-05-25 王冬梅 主治动脉粥样硬化的中药组合物及制法
TWI750189B (zh) * 2016-12-15 2021-12-21 大陸商深圳瑞健生命科學研究院有限公司 一種治療冠狀動脈粥樣硬化及其併發症的方法
EP3658581A1 (en) * 2017-07-24 2020-06-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies and peptides to treat hcmv related diseases
CN111773440B (zh) * 2020-05-22 2026-04-17 南京大学 一种基于类酶催化反应的抗凝血材料
CN117244043B (zh) * 2023-11-02 2024-09-20 徐州医科大学附属医院 破伤风类毒素在治疗血管内皮细胞损伤中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410022B1 (en) * 1995-05-01 2002-06-25 Avant Immunotherapeutics, Inc. Modulation of cholesteryl ester transfer protein (CETP) activity
AT500835B1 (de) * 2004-09-13 2007-12-15 Affiris Forschungs & Entwicklungs Gmbh Cholinestertransport-protein-mimotop als atherosklerose-medikament
US20060276400A1 (en) 2005-06-06 2006-12-07 Hedy Adari Modulation of cholesteryl ester transfer protein (CETP) activity
RU2008123518A (ru) * 2005-11-10 2009-12-20 Ресептор Байолоджикс, Инк. (Us) Способы получения изоформ рецепторов и лигандов

Also Published As

Publication number Publication date
TW200911282A (en) 2009-03-16
SI2190451T1 (sl) 2013-12-31
TWI442933B (zh) 2014-07-01
US20140179900A1 (en) 2014-06-26
US8618046B2 (en) 2013-12-31
EP2190451B1 (en) 2013-10-16
PL2190451T3 (pl) 2014-03-31
ES2439703T3 (es) 2014-01-24
DK2190451T3 (da) 2013-11-04
JP2014040438A (ja) 2014-03-06
AU2008286667A1 (en) 2009-02-19
EP2190451A1 (en) 2010-06-02
PT2190451E (pt) 2013-12-23
AU2008286667B2 (en) 2013-04-04
JP2010535818A (ja) 2010-11-25
CN101835483A (zh) 2010-09-15
CN101835483B (zh) 2012-09-26
CA2695988A1 (en) 2009-02-19
HRP20131229T1 (hr) 2014-01-31
KR20100080507A (ko) 2010-07-08
US20110275556A1 (en) 2011-11-10
HK1145634A1 (en) 2011-04-29
CY1114760T1 (el) 2016-12-14
AT505574A1 (de) 2009-02-15
WO2009021254A1 (en) 2009-02-19

Similar Documents

Publication Publication Date Title
DE69636453T2 (de) Modulation der aktivität des cholesteryl-ester-transfer-proteins (cetp)
DE60103137T2 (de) Impstoff zur behandlung von atherosclerosis
AT506535B1 (de) Vaccine enthaltend alpha-synuclein-mimotope auf basis von peptiden
AT509611B1 (de) Vakzin
KR102468907B1 (ko) 질환의 요인이 되는 생체내 단백질을 표적으로 하는 컨쥬게이트 백신
AT505574A1 (de) Pharmazeutische zusammensetzung
KR101983685B1 (ko) 백신
KR20110036809A (ko) 파킨슨병과 관련된 증상을 치료하기 위한 화합물
AT508638A1 (de) Mimotope
AT500835B1 (de) Cholinestertransport-protein-mimotop als atherosklerose-medikament
WO2010057242A2 (de) Vakzin
WO2012059573A1 (de) Immunogenes peptid
US9029327B2 (en) Vaccine
HK1145634B (en) Treatment of atherosclerosis
TW201420112A (zh) 胜肽、醫藥化合物及該醫藥化合物之使用
EP2532359A1 (en) CETP fragments
HK1170248A (en) Immunogenes peptide

Legal Events

Date Code Title Description
MM01 Lapse because of not paying annual fees

Effective date: 20150810